Our coverage is unrivalled in its depth, geographic scope and local insights. We enable you to make informed and strategic decisions in an ever-changing and highly competitive market.
Our medical device intelligence covers 16 key therapy areas and is available through comprehensive device modules to offer clients complete flexibility of choice.
We produce thousands of quantitative and qualitative reports annually, instantly available, to help you make more informed decisions quickly.
Our Intelligence Centers offer constantly updated data, investigative news, analysis and tools that slot seamlessly into your workflow to help you decode the future.
For fully bespoke independent insight with dedicated expert service, our consulting offering combines global capabilities with strong understanding of your local markets.
Following today’s announcement (12 October) from Sajid Javid, UK Home Secretary, that physicians can now prescribe cannabis oil to patients from 1st November,
The recently announced Gilead deal with the NHS which will allow some adult NHS patients suffering from large B-cell lymphoma (DLBCL) to gain access to its CART-T cell therapy, Yescarta, will place...
Novo Nordisk’s NN9924 is on track to become the first-to-market oral GLP-1RA within the next decade, says
contact online firstname.lastname@example.org
EMEA: +44 207 832 4399
APAC: +91 40 6616 6809
© GlobalData Plc 2018 | Registered Office: John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK Registered in England No. 03925319